Table 2 Frequency of clinical manifestations of congenital toxoplasmosis in newborns from mothers treated with spiramycin (Group 1) and from untreated mothers (Group 2)
Any of the following clinical signs | Group 1 | Group 2 | pa |
|---|---|---|---|
|  | (N = 27) | (N = 19) |  |
| Â | n% | n% | Â |
Presence | 8 (29,63) | 13 (68,42) | 0,0963 |
Cerebral calcification | 1 (3,70) | 3 (15,79) | 0,2190 |
Hydrocephalus | - | 5 (26,32) | 0,0181 |
Microcephaly | - | 2 (10,53) | 0,1862 |
Blindness | - | 2 (10,53) | 0,1862 |
Chorioretinitis | 1 (3,70) | 3 (15,79) | 0,2190 |
Corticosubcortical dysfunction | 2 (7,40) | 3 (15,79) | 0,3677 |
Systemic toxoplasmosis | - | 1 (5,26) | 0,4255 |
Optic neuropathy | - | 4 (21,05) | 0,0384 |
Hepatosplenomegaly | - | 2 (10,53) | 0,1862 |
Hearing dysfunction | 4 (14,80) | 1 (5,26) | 0,3402 |
Generalized lymphoglandular form | 1 (3,70) | - | 0,5957 |